Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure

Current Topics in Medicinal Chemistry

Volumn 13, Issue 13, 2013, Pages 1548-1558

  Oikonomou, Evangelos ^a   Siasos, Gerasimos ^a   Tousoulis, Dimitris ^a   Kokkou, Eleni ^a   Genimata, Vasiliki ^a   Zisimos, Konstantinos ^a   Latsios, George ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Biomarkers; Heart failure; MicroRNA; Myocardial hypertrophy; Prognosis; Treatment

Indexed keywords

DOXORUBICIN; MICRORNA; MICRORNA 1; MICRORNA 125B; MICRORNA 133; MICRORNA 195; MICRORNA 199A; MICRORNA 208; MICRORNA 499; MITOGEN ACTIVATED PROTEIN KINASE; OLIGONUCLEOTIDE; RYANODINE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; HEART FAILURE; HEART INJURY; HEART VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MITOCHONDRION; NONHUMAN; PROGNOSIS; REVIEW; VIRUS MYOCARDITIS;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; MICRORNAS; PROGNOSIS;

EID: 84881345171     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113139990104     Document Type: Review

References (95)

1. McMurray, J. J.; Adamopoulos, S.; Anker, S. D.; Auricchio, A.; Bohm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Sanchez, M. A.; Jaarsma, T.; Kober, L.; Lip, G. Y.; Maggioni, A. P.; Parkhomenko, A.; Pieske, B. M.; Popescu, B. A.; Ronnevik, P. K.; Rutten, F. H.; Schwitter, J.; Seferovic, P.; Stepinska, J.; Trindade, P. T.; Voors, A. A.; Zannad, F.; Zeiher, A.; Bax, J. J.; Baumgartner, H.; Ceconi, C.; Dean, V.; Deaton, C.; Fagard, R.; Funck-Brentano, C.; Hasdai, D.; Hoes, A.; Kirchhof, P.; Knuuti, J.; Kolh, P.; McDonagh, T.; Moulin, C.; Reiner, Z.; Sechtem, U.; Sirnes, P. A.; Tendera, M.; Torbicki, A.; Vahanian, A.; Windecker, S.; Bonet, L. A.; Avraamides, P.; Ben Lamin, H. A.; Brignole, M.; Coca, A.; Cowburn, P.; Dargie, H.; Elliott, P.; Flachskampf, F. A.; Guida, G. F.; Hardman, S.; Iung, B.; Merkely, B.; Mueller, C.; Nanas, J. N.; Nielsen, O. W.; Orn, S.; Parissis, J. T.; Ponikowski, P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 2012.
2. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J. J.; Ponikowski, P.; Poole-Wilson, P. A.; Stromberg, A.; van Veldhuisen, D. J.; Atar, D.; Hoes, A. W.; Keren, A.; Mebazaa, A.; Nieminen, M.; Priori, S. G.; Swedberg, K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fai. l, 2008, 10(10), 933-989.
3. Gounari, P.; Tousoulis, D.; Antoniades, C.; Kampoli, A. M.; Stougiannos, P.; Papageorgiou, N.; Roulia, G.; Stefanadi, E.; Siasos, G.; Tsioufis, C.; Stefanadis, C. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int. J. Cardiol., 2010, 142(1), 87-91.
4. Tousoulis, D.; Charakida, M.; Stefanadi, E.; Siasos, G.; Latsios, G.; Stefanadis, C. Statins in heart failure. Beyond the lipid lowering effect. Int. J. Cardiol., 2007, 115(2), 144-150.
5. Oikonomou, E.; Tousoulis, D.; Siasos, G.; Zaromitidou, M.; Papavassiliou, A. G.; Stefanadis, C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J. Cardiol., 2011, 52(1), 30-40.
6. Tousoulis, D.; Oikonomou, E.; Siasos, G.; Chrysohoou, C.; Charakida, M.; Trikas, A.; Siasou, Z.; Limperi, M.; Papadimitriou, E. D.; Papavassiliou, A. G.; Stefanadis, C. Predictive value of biomarkers in patients with heart failure. Curr. Med. Chem., 2012, 19(16), 2534-2547.
7. Tousoulis, D.; Drolias, A.; Antoniades, C.; Vasiliadou, C.; Marinou, K.; Latsios, G.; Stefanadi, E.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Trikas, A.; Stefanadis, C. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int. J. Cardiol., 2009, 134(2), 238-243.
8. Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis, 2010, 210(1), 194-198.
9. Tousoulis, D.; Kampoli, A. M.; Siasos, G.; Stefanadi, E.; Antoniades, C.; Papavassiliou, A. G.; Stefanadis, C. Circulating biomarkers for the diagnosis and prognosis of heart failure. Curr. Med. Chem., 2009, 16(29), 3828-3840.
10. Tousoulis, D.; Antonopoulos, A. S.; Antoniades, C.; Saldari, C.; Stefanadi, E.; Siasos, G.; Stougianos, P.; Plastiras, A.; Korompelis, P.; Stefanadis, C. Role of depression in heart failure--choosing the right antidepressive treatment. Int. J. Cardiol., 2010, 140(1), 12-18.
11. Tousoulis, D.; Briasoulis, A.; Papageorgiou, N.; Antoniades, C.; Stefanadis, C. Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends Mol. Med., 2008, 14(10), 441-449.
12. Papageorgiou, N.; Tousoulis, D.; Androulakis, E.; Kontogeorgou, A.; Charakida, M.; Giolis, A.; Siama, K.; Trikas, A.; Briasoulis, A.; Pitsavos, C.; Stefanadis, C. The role of microRNAs in the initiation and progression of stable atheromatous plaque. Curr. Pharm. Des., 2012.
13. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2), 281-297.
14. Zhang, R.; Su, B. Small but influential: the role of microRNAs on gene regulatory network and 3'UTR evolution. J. Genet. Genomics, 2009, 36(1), 1-6.
15. Thum, T.; Catalucci, D.; Bauersachs, J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc. Res., 2008, 79(4), 562-570.
16. Pan, Z. W.; Lu, Y. J.; Yang, B. F. MicroRNAs: a novel class of potential therapeutic targets for cardiovascular diseases. Acta. Pharmacol. Sin., 2010, 31(1), 1-9.
17. Ono, K.; Kuwabara, Y.; Han, J. MicroRNAs and cardiovascular diseases. FEBS J., 2011, 278(10), 1619-1633.
18. Hunter, M. P.; Ismail, N.; Zhang, X.; Aguda, B. D.; Lee, E. J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M. L.; Schmittgen, T. D.; Nana-Sinkam, S. P.; Jarjoura, D.; Marsh, C. B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS. One, 2008, 3(11), e3694.
19. Zhu, H.; Fan, G. C. Extracellular/circulating microRNAs and their potential role in cardiovascular disease. Am. J. Cardiovasc. Dis., 2011, 1(2), 138-149.
20. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.; Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N.; Bentwich, Z.; Hod, M.; Goren, Y.; Chajut, A. Serum microRNAs are promising novel biomarkers. PLoS. One, 2008, 3(9), e3148.
21. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol., 2002, 12(9), 735-739.
22. Papageorgiou, N.; Tousoulis, D.; Androulakis, E.; Siasos, G.; Briasoulis, A.; Vogiatzi, G.; Kampoli, A. M.; Tsiamis, E.; Tentolouris, C.; Stefanadis, C. The role of microRNAs in cardiovascular disease. Curr. Med. Chem., 2012, 19(16), 2605-2610.
23. Condorelli, G.; Latronico, M. V.; Dorn, G. W. 2nd microRNAs in heart disease: putative novel therapeutic targets? Eur. Heart J., 2010, 31(6), 649-658.
24. Garofalo, M.; Condorelli, G.; Croce, C. M. MicroRNAs in diseases and drug response. Curr. Opin. Pharmacol., 2008, 8(5), 661-667.
25. Zhao, Y.; Ransom, J. F.; Li, A.; Vedantham, V.; von Drehle, M.; Muth, A. N.; Tsuchihashi, T.; McManus, M. T.; Schwartz, R. J.; Srivastava, D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell, 2007, 129(2), 303-317.
26. Chen, J. F.; Murchison, E. P.; Tang, R.; Callis, T. E.; Tatsuguchi, M.; Deng, Z.; Rojas, M.; Hammond, S. M.; Schneider, M. D.; Selzman, C. H.; Meissner, G.; Patterson, C.; Hannon, G. J.; Wang, D. Z. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(6), 2111-2116.
27. da Costa Martins, P. A.; Bourajjaj, M.; Gladka, M.; Kortland, M.; van Oort, R. J.; Pinto, Y. M.; Molkentin, J. D.; De Windt, L. J. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation, 2008, 118(15), 1567-1576.
28. Williams, A. H.; Liu, N.; van Rooij, E.; Olson, E. N. MicroRNA control of muscle development and disease. Curr. Opin. Cell Biol., 2009, 21(3), 461-469.
29. Wang, Z.; Luo, X.; Lu, Y.; Yang, B. miRNAs at the heart of the matter. J. Mol. Med. (Berl), 2008, 86(7), 771-783.
30. Oliveira-Carvalho, V.; Silva, M. M.; Guimaraes, G. V.; Bacal, F.; Bocchi, E. A. MicroRNAs: new players in heart failure. Mol. Biol. Rep., 2012.
31. Yang, W. J.; Yang, D. D.; Na, S.; Sandusky, G. E.; Zhang, Q.; Zhao, G. Dicer is required for embryonic angiogenesis during mouse development. J. Biol. Chem., 2005, 280(10), 9330-9335.
32. Kwon, C.; Han, Z.; Olson, E. N.; Srivastava, D. MicroRNA1 influences cardiac differentiation in Drosophila and regulates Notch signaling. Proc Natl Acad Sci U S A, 2005, 102(52), 18986-18991.
33. Foshay, K. M.; Gallicano, G. I. Small RNAs, big potential: the role of MicroRNAs in stem cell function. Curr Stem Cell Res Ther, 2007, 2(4), 264-271.
34. Care, A.; Catalucci, D.; Felicetti, F.; Bonci, D.; Addario, A.; Gallo, P.; Bang, M. L.; Segnalini, P.; Gu, Y.; Dalton, N. D.; Elia, L.; Latronico, M. V.; Hoydal, M.; Autore, C.; Russo, M. A.; Dorn, G. W. 2nd; Ellingsen, O.; Ruiz-Lozano, P.; Peterson, K. L.; Croce, C. M.; Peschle, C.; Condorelli, G. MicroRNA-133 controls cardiac hypertrophy. Nat Med, 2007, 13(5), 613-618.
35. van Rooij, E.; Sutherland, L. B.; Qi, X.; Richardson, J. A.; Hill, J.; Olson, E. N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 2007, 316(5824), 575-579.
36. Sluijter, J. P.; van Mil, A.; van Vliet, P.; Metz, C. H.; Liu, J.; Doevendans, P. A.; Goumans, M. J. MicroRNA-1 and-499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler. Thromb. Vasc. Biol., 2010, 30(4), 859-868.
37. Vacchi-Suzzi, C.; Hahne, F.; Scheubel, P.; Marcellin, M.; Dubost, V.; Westphal, M.; Boeglen, C.; Buchmann-Moller, S.; Cheung, M. S.; Cordier, A.; De Benedetto, C.; Deurinck, M.; Frei, M.; Moulin, P.; Oakeley, E.; Grenet, O.; Grevot, A.; Stull, R.; Theil, D.; Moggs, J. G.; Marrer, E.; Couttet, P. Heart Structure-Specific Transcriptomic Atlas Reveals Conserved microRNA-mRNA Interactions. PLoS. One, 2013, 8(1), e52442.
38. Schneider, M.; Andersen, D. C.; Silahtaroglu, A.; Lyngbaek, S.; Kauppinen, S.; Hansen, J. L.; Sheikh, S. P. Cell-specific detection of microRNA expression during cardiomyogenesis by combined in situ hybridization and immunohistochemistry. J. Mol. Histol., 2011, 42(4), 289-299.
39. Sucharov, C.; Bristow, M. R.; Port, J. D. miRNA expression in the failing human heart: functional correlates. J. Mol. Cell. Cardiol., 2008, 45(2), 185-192.
40. Li, D.; Yang, P.; Xiong, Q.; Song, X.; Yang, X.; Liu, L.; Yuan, W.; Rui, Y. C. MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J. Hypertens., 2010, 28(8), 1646-1654.
41. van Rooij, E.; Sutherland, L. B.; Liu, N.; Williams, A. H.; McAnally, J.; Gerard, R. D.; Richardson, J. A.; Olson, E. N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(48), 18255-18260.
42. Suckau, L.; Fechner, H.; Chemaly, E.; Krohn, S.; Hadri, L.; Kockskamper, J.; Westermann, D.; Bisping, E.; Ly, H.; Wang, X.; Kawase, Y.; Chen, J.; Liang, L.; Sipo, I.; Vetter, R.; Weger, S.; Kurreck, J.; Erdmann, V.; Tschope, C.; Pieske, B.; Lebeche, D.; Schultheiss, H. P.; Hajjar, R. J.; Poller, W. C. Long-term cardiactargeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation, 2009, 119(9), 1241-1252.
43. Lagos-Quintana, M.; Rauhut, R.; Meyer, J.; Borkhardt, A.; Tuschl, T. New microRNAs from mouse and human. RNA, 2003, 9(2), 175-179.
44. Siasos, G.; Tousoulis, D.; Vlachopoulos, C.; Antoniades, C.; Stefanadi, E.; Ioakeimidis, N.; Zisimos, K.; Siasou, Z.; Papavassiliou, A. G.; Stefanadis, C. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. Am. J. Hypertens., 2009, 22(6), 586-592.
45. Tousoulis, D.; Oikonomou, E.; Siasos, G.; Chrysohoou, C.; Zaromitidou, M.; Kioufis, S.; Maniatis, K.; Dilaveris, P.; Miliou, A.; Michalea, S.; Papavassiliou, A. G.; Stefanadis, C. Dosedependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis, 2013, 227(2), 367-372.
46. Tousoulis, D.; Kampoli, A. M.; Papageorgiou, N.; Antoniades, C.; Siasos, G.; Latsios, G.; Tsiamis, E.; Stefanadis, C. Matrix metallopropteinases in heart failure. Curr. Top. Med. Chem., 2012, 12(10), 1181-1191.
47. Stefanadi, E.; Tousoulis, D.; Androulakis, E. S.; Papageorgiou, N.; Charakida, M.; Siasos, G.; Tsioufis, C.; Stefanadis, C. Inflammatory markers in essential hypertension: potential clinical implications. Curr. Vasc. Pharmacol., 2010, 8(4), 509-516.
48. Siasos, G.; Tousoulis, D.; Siasou, Z.; Stefanadis, C.; Papavassiliou, A. G. Shear stress, protein kinases and atherosclerosis. Curr. Med. Chem., 2007, 14(14), 1567-1572.
49. Thum, T.; Galuppo, P.; Wolf, C.; Fiedler, J.; Kneitz, S.; van Laake, L. W.; Doevendans, P. A.; Mummery, C. L.; Borlak, J.; Haverich, A.; Gross, C.; Engelhardt, S.; Ertl, G.; Bauersachs, J. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation, 2007, 116(3), 258-267.
50. Ikeda, S.; He, A.; Kong, S. W.; Lu, J.; Bejar, R.; Bodyak, N.; Lee, K. H.; Ma, Q.; Kang, P. M.; Golub, T. R.; Pu, W. T. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol. Cell Biol., 2009, 29(8), 2193-2204.
51. Sayed, D.; Hong, C.; Chen, I. Y.; Lypowy, J.; Abdellatif, M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ. Res., 2007, 100(3), 416-424.
52. Ikeda, S.; Kong, S. W.; Lu, J.; Bisping, E.; Zhang, H.; Allen, P. D.; Golub, T. R.; Pieske, B.; Pu, W. T. Altered microRNA expression in human heart disease. Physiol. Genomics, 2007, 31(3), 367-373.
53. Matkovich, S. J.; Van Booven, D. J.; Youker, K. A.; Torre-Amione, G.; Diwan, A.; Eschenbacher, W. H.; Dorn, L. E.; Watson, M. A.; Margulies, K. B.; Dorn, G. W. 2nd Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation, 2009, 119(9), 1263-1271.
54. Han, M.; Toli, J.; Abdellatif, M. MicroRNAs in the cardiovascular system. Curr. Opin. Cardiol., 2011, 26(3), 181-189.
55. Dong, D. L.; Chen, C.; Huo, R.; Wang, N.; Li, Z.; Tu, Y. J.; Hu, J. T.; Chu, X.; Huang, W.; Yang, B. F. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy. Hypertension, 2010, 55(4), 946-952.
56. Feng, B.; Chen, S.; George, B.; Feng, Q.; Chakrabarti, S. miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab. Res. Rev., 2010, 26(1), 40-49.
57. Ucar, A.; Gupta, S. K.; Fiedler, J.; Erikci, E.; Kardasinski, M.; Batkai, S.; Dangwal, S.; Kumarswamy, R.; Bang, C.; Holzmann, A.; Remke, J.; Caprio, M.; Jentzsch, C.; Engelhardt, S.; Geisendorf, S.; Glas, C.; Hofmann, T. G.; Nessling, M.; Richter, K.; Schiffer, M.; Carrier, L.; Napp, L. C.; Bauersachs, J.; Chowdhury, K.; Thum, T. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun., 2012, 3, 1078.
58. He, J.; Jiang, S.; Li, F. L.; Zhao, X. J.; Chu, E. F.; Sun, M. N.; Chen, M. Z.; Li, H. MicroRNA-30b-5p Is Involved in the Regulation of Cardiac Hypertrophy by Targeting CaMKIIdelta. J. Investig. Med., 2013.
59. Li, R. C.; Tao, J.; Guo, Y. B.; Wu, H. D.; Liu, R. F.; Bai, Y.; Lv, Z. Z.; Luo, G. Z.; Li, L. L.; Wang, M.; Yang, H. Q.; Gao, W.; Han, Q. D.; Zhang, Y. Y.; Wang, X.; Xu, M.; Wang, S. Q. In vivo Suppression of MiR-24 Prevents the Transition toward Decompensated Hypertrophy in Aortic-constricted Mice. Circ. Res., 2013.
60. Duan, Y.; Zhou, B.; Su, H.; Liu, Y.; Du, C. miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp. Cell Res., 2013, 319(3), 173-184.
61. Ge, Y.; Pan, S.; Guan, D.; Yin, H.; Fan, Y.; Liu, J.; Zhang, S.; Zhang, H.; Feng, L.; Wang, Y.; Xu, R.; Yin, J. Q. MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Biochim. Biophys. Acta., 2013, 1832(1), 1-10.
62. Wang, K.; Lin, Z. Q.; Long, B.; Li, J. H.; Zhou, J.; Li, P. F. Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J. Biol. Chem., 2012, 287(1), 589-599.
63. Greco, S.; Fasanaro, P.; Castelvecchio, S.; D'Alessandra, Y.; Arcelli, D.; Di Donato, M.; Malavazos, A.; Capogrossi, M. C.; Menicanti, L.; Martelli, F. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes, 2012, 61(6), 1633-1641.
64. Tijsen, A. J.; Creemers, E. E.; Moerland, P. D.; de Windt, L. J.; van der Wal, A. C.; Kok, W. E.; Pinto, Y. M. MiR423-5p as a circulating biomarker for heart failure. Circ. Res., 2010, 106(6), 1035-1039.
65. Nair, N.; Kumar, S.; Gongora, E.; Gupta, S. Circulating miRNA as novel markers for diastolic dysfunction. Mol. Cell Biochem., 2012.
66. Zhang, R.; Niu, H.; Ban, T.; Xu, L.; Li, Y.; Wang, N.; Sun, L.; Ai, J.; Yang, B. Elevated plasma microRNA-1 predicts heart failure after acute myocardial infarction. Int. J. Cardiol., 2012.
67. Blanco, R. R.; Austin, H.; Vest, R. N. 3rd; Valadri, R.; Li, W.; Lassegue, B.; Song, Q.; London, B.; Dudley, S. C.; Bloom, H. L.; Searles, C. D.; Zafari, A. M. Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure. J. Card. Fail., 2012, 18(9), 717-723.
68. Endo, K.; Naito, Y.; Ji, X.; Nakanishi, M.; Noguchi, T.; Goto, Y.; Nonogi, H.; Ma, X.; Weng, H.; Hirokawa, G.; Asada, T.; Kakinoki, S.; Yamaoka, T.; Fukushima, Y.; Iwai, N. MicroRNA 210 as a Biomarker for Congestive Heart Failure. Biol. Pharm. Bull., 2013, 36(1), 48-54.
69. Kawamoto, A.; Asahara, T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc. Interv., 2007, 70(4), 477-484.
70. Tousoulis, D.; Andreou, I.; Tsiatas, M.; Miliou, A.; Tentolouris, C.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis, 2011, 214(1), 151-157.
71. Alba, A. C.; Delgado, D. H.; Rao, V.; Walter, S.; Guyatt, G.; Ross, H. J. Are endothelial progenitor cells a prognostic factor in patients with heart failure? Expert Rev. Cardiovasc. Ther., 2012, 10(2), 167-175.
72. Maltais, S.; Perrault, L. P.; Ly, H. Q. The bone marrow-cardiac axis: role of endothelial progenitor cells in heart failure. Eur. J. Cardiothorac Surg., 2011, 39(3), 368-374.
73. Qiang, L.; Hong, L.; Ningfu, W.; Huaihong, C.; Jing, W. Expression of miR-126 and miR-508-5p in endothelial progenitor cells is associated with the prognosis of chronic heart failure patients. Int. J. Cardiol., 2013.
74. Eitel, I.; Adams, V.; Dieterich, P.; Fuernau, G.; de Waha, S.; Desch, S.; Schuler, G.; Thiele, H. Relation of circulating MicroRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J., 2012, 164(5), 706-714.
75. Vacchi-Suzzi, C.; Bauer, Y.; Berridge, B. R.; Bongiovanni, S.; Gerrish, K.; Hamadeh, H. K.; Letzkus, M.; Lyon, J.; Moggs, J.; Paules, R. S.; Pognan, F.; Staedtler, F.; Vidgeon-Hart, M. P.; Grenet, O.; Couttet, P. Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS. One, 2012, 7(7), e40395.
76. Dickinson, B. A.; Semus, H. M.; Montgomery, R. L.; Stack, C.; Latimer, P. A.; Lewton, S. M.; Lynch, J. M.; Hullinger, T. G.; Seto, A. G.; van Rooij, E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertensioninduced heart failure. Eur. J. Heart Fail., 2013.
77. Limana, F.; Esposito, G.; D'Arcangelo, D.; Di Carlo, A.; Romani, S.; Melillo, G.; Mangoni, A.; Bertolami, C.; Pompilio, G.; Germani, A.; Capogrossi, M. C. HMGB1 attenuates cardiac remodelling in the failing heart via enhanced cardiac regeneration and miR-206-mediated inhibition of TIMP-3. PLoS. One, 2011, 6(6), e19845.
78. Ramani, R.; Vela, D.; Segura, A.; McNamara, D.; Lemster, B.; Samarendra, V.; Kormos, R.; Toyoda, Y.; Bermudez, C.; Frazier, O. H.; Moravec, C. S.; Gorcsan, J. 3rd; Taegtmeyer, H.; McTiernan, C. F. A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure. J. Am. Coll. Cardiol., 2011, 58(22), 2270-2278.
79. Villar, A. V.; Merino, D.; Wenner, M.; Llano, M.; Cobo, M.; Montalvo, C.; Garcia, R.; Martin-Duran, R.; Hurle, J. M.; Hurle, M. A.; Nistal, J. F. Myocardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart, 2011, 97(14), 1132-1137.
80. Chen, J.; Normand, S. L.; Wang, Y.; Krumholz, H. M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA, 2011, 306(15), 1669-1678.
81. McMurray, J. J. Clinical practice. Systolic heart failure. N. Engl. J. Med., 2010, 362(3), 228-238.
82. Dunlay, S. M.; Redfield, M. M.; Weston, S. A.; Therneau, T. M.; Hall Long, K.; Shah, N. D.; Roger, V. L. Hospitalizations after heart failure diagnosis a community perspective. J. Am. Coll. Cardiol., 2009, 54(18), 1695-1702.
83. Fukushima, Y.; Nakanishi, M.; Nonogi, H.; Goto, Y.; Iwai, N. Assessment of plasma miRNAs in congestive heart failure. Circ. J., 2011, 75(2), 336-340.
84. van Rooij, E.; Marshall, W. S.; Olson, E. N. Toward microRNAbased therapeutics for heart disease: the sense in antisense. Circ. Res., 2008, 103(9), 919-928.
85. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438(7068), 685-689.
86. van Rooij, E.; Sutherland, L. B.; Thatcher, J. E.; DiMaio, J. M.; Naseem, R. H.; Marshall, W. S.; Hill, J. A.; Olson, E. N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(35), 13027-13032.
87. Ebert, M. S.; Neilson, J. R.; Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods, 2007, 4(9), 721-726.
88. Xiao, J.; Yang, B.; Lin, H.; Lu, Y.; Luo, X.; Wang, Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J. Cell Physiol., 2007, 212(2), 285-292.
89. Sayed, D.; Rane, S.; Lypowy, J.; He, M.; Chen, I. Y.; Vashistha, H.; Yan, L.; Malhotra, A.; Vatner, D.; Abdellatif, M. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol. Biol. Cell., 2008, 19(8), 3272-3282.
90. Montgomery, R. L.; Hullinger, T. G.; Semus, H. M.; Dickinson, B. A.; Seto, A. G.; Lynch, J. M.; Stack, C.; Latimer, P. A.; Olson, E. N.; van Rooij, E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation, 2011, 124(14), 1537-1547.
91. Thum, T.; Gross, C.; Fiedler, J.; Fischer, T.; Kissler, S.; Bussen, M.; Galuppo, P.; Just, S.; Rottbauer, W.; Frantz, S.; Castoldi, M.; Soutschek, J.; Koteliansky, V.; Rosenwald, A.; Basson, M. A.; Licht, J. D.; Pena, J. T.; Rouhanifard, S. H.; Muckenthaler, M. U.; Tuschl, T.; Martin, G. R.; Bauersachs, J.; Engelhardt, S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456(7224), 980-984.
92. Patrick, D. M.; Montgomery, R. L.; Qi, X.; Obad, S.; Kauppinen, S.; Hill, J. A.; van Rooij, E.; Olson, E. N. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest., 2010, 120(11), 3912-3916.
93. Li, R. C.; Tao, J.; Guo, Y. B.; Wu, H. D.; Liu, R. F.; Bai, Y.; Lv, Z. Z.; Luo, G. Z.; Li, L. L.; Wang, M.; Yang, H. Q.; Gao, W.; Han, Q. D.; Zhang, Y. Y.; Wang, X. J.; Xu, M.; Wang, S. Q. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ. Res., 2013, 112(4), 601-605.
94. Corsten, M. F.; Papageorgiou, A.; Verhesen, W.; Carai, P.; Lindow, M.; Obad, S.; Summer, G.; Coort, S. L.; Hazebroek, M.; van Leeuwen, R.; Gijbels, M. J.; Wijnands, E.; Biessen, E. A.; De Winther, M. P.; Stassen, F. R.; Carmeliet, P.; Kauppinen, S.; Schroen, B.; Heymans, S. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ. Res., 2012, 111(4), 415-425.
95. Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; Li, Q.; Li, X.; Wang, W.; Wang, J.; Jiang, X.; Xiang, Y.; Xu, C.; Zheng, P.; Zhang, J.; Li, R.; Zhang, H.; Shang, X.; Gong, T.; Ning, G.; Zen, K.; Zhang, C. Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res., 2008, 18(10), 997-1006.